Solriamfetol Dose B

DRUG2 trials

Sponsors

Axsome Therapeutics, Inc.

Conditions

ADHD

Phase 3

Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)

RecruitingNCT07717892

Axsome Therapeutics, Inc.ADHD

Start: 2026-06-25End: 2028-06-30Target: 468Updated: 2026-09-08

Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)

RecruitingNCT07717879

Axsome Therapeutics, Inc.ADHD

Start: 2026-07-06End: 2028-06-30Target: 468Updated: 2026-09-08